PDF Archive search engine
Last database update: 11 May at 22:48 - Around 76000 files indexed.

Show results per page

Results for «kinase»:

Total: 36 results - 0.062 seconds

Patrick Connolly CV 100%

Patrick Connolly Postgraduate Researcher, National University of Ireland Galway.


葉振聲 93%

Measurement of creatinine kinase isoforms by agarose gel electrophoresis.


Treatment of Neuroinflammation in Alzheimer's Disease. 88%

Aβ stimulates NFκB activation and extracellular kinase pathways which lead to cytokine or chemokine production (19,20).


m140006 84%

Abstract To elucidate the mechanism of bromodeoxyuridine (BrdU (BrdU)) induced cellular senescence, we treated HeLa cells with D4476, a potent and specific inhibitor of casein kinase 1(CK1).


Hilfreiches bei Krebs 83%

The modulatory effects of CHL on the hallmark capabilities of cancer appear to be mediated via abrogation of key oncogenic signal transduction pathways such as nuclear factor kappa B, Wnt/βcatenin, and phosphatidylinositol-3-kinase/Akt signaling.


Abstract 80%

They are also sensitive to EGFR tyrosine kinase inhibitors (TKIs), which provide superior clinical benefits to conventional chemotherapy.


Ⅳ期维吾尔族 NSCLC 患者 EML4-ALK、 EGFR 基因突变状态及生存分析 77%

癌, 非小细胞肺;受体, 表皮生长因子;突变;维吾尔族;非小细胞肺癌;棘皮动物微管样蛋白 4-间变淋巴 瘤激酶;生存分析 中图分类号:R734.2 文献标志码: A DOI: 10.11958/58911 EML4-ALK and EGFR mutation status and survival analysis in Uygur with stage Ⅳ NSCLC WANG Qiang1, ZHANG Qiao1, CAO Yanzhen2, TAO Jie1, SHAN Li1△ 1 Department of Medical Oncology, 2 Department of Pathology, Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi 830011, China △ Corresponding Author Abstract:Objective E-mail: To investigate the relationship between the echinoderm microtubule associated protein like 4- anaplastic lymphoma kinase (EML4-ALK) and epithelial growth factor receptor (EGFR) mutation status and overall survival (OS) in Uygur patients with stage Ⅳ non-small cell lung cancer (NSCLC) who did not accept tyrosine kinase inhibitor treat⁃ ment.


JDIT-2018-0210-030 75%

Once inside the cell, [18F]FLT is a substrate for thymidine kinase I (TK1) and is phosphorylated but is not incorporated into DNA.


印度抗癌药舒尼替尼 71%

印度抗癌药舒尼替尼 舒尼替尼由辉瑞公司生产,是一种口服的小分子多靶点受体酪氨酸激酶抑制剂(receptor tyrosine kinase inhibitor ,rTKI)。具有抑制肿瘤血管生成和抗肿瘤细胞生长的多重作用。该药 发挥抗癌作用的靶点包括:PDGFR(PDGFRα和 PDGFRβ),VEGFR(VEGFR1、VEGFR2、 VEGFR3),FLT-3, CSF-1R,kit 和 ret.


治疗晚期肾癌药品舒尼替尼价格 71%

治疗晚期肾癌药品舒尼替尼价格 舒尼替尼胶囊说明: 舒尼替尼胶囊 Sunitinib Malate Capsules,由辉瑞公司生产,是一种口服的小分子多靶点受 体酪氨酸激酶抑制剂(receptor tyrosine kinase inhibitor ,rTKI)。具有抑制肿瘤血管生成和抗肿 瘤细胞生长的多重作用。该药发挥抗癌作用的靶点包括:PDGFR(PDGFRα和 PDGFR β),VEGFR(VEGFR1、VEGFR2、VEGFR3),FLT-3, CSF-1R,kit 和 ret。该药上市十几年来,基于大 量临床研究证据,已被多个国家和地区的医学指南推荐作为晚期肾细胞癌的一线治疗药物 (如美国、加拿大、欧洲、中国等)。该药在中国大陆的适应症为:1 甲磺酸伊马替尼治疗 失败或不能耐受的胃肠间质瘤(GIST);2 不能手术的晚期肾细胞癌(RCC);3 不可切除 的,转移性高分化进展期胰腺神经内分泌瘤(pNET)成年患者,本品作为一线治疗的经验 有限。 在国内晚期肾细胞癌的治疗方面,由于其起效迅速、耐受性良好,能够快速控制肿 瘤症状、与其他靶向药物相比具有较高的临床有效率、能够有效的控制肿瘤的进展,已得 到泌尿外科医生和肿瘤内科医生的普遍认可。由于舒尼替尼针对许多不同受体,它也带来 很多副作用,例如手足综合征、口腔炎和其它皮肤和皮下组织异常。随着临床用药经验的 丰富和个体化用药策略的实施,药物相关的不良反应已经得到有效的控制。 舒尼替尼胶囊价格: 由于舒尼替尼胶囊有良好的治愈效果,目前国内的价格大概在 131800 元/盒,这是在国内 市场调查的平均价格,跟实际价格还是有点差别的。但是在 apolopharmacy 上的价格大约 在 6000 元左右,由于每天的汇率都有所差异,具体的价格还是要根据你当天实际付款的价 格来了,不过价格相差也不会太大。 印度抗癌药品更多详情咨询 电话:0091-9205113743 电子邮箱 官网


to 69%

protein kinase C, PKC, EC należy do rodziny kinaz białkowych - enzymów, które są zaangażowane w kontrolowanie funkcjonowania innych białek, poprzez fosforylację grup hydroksylowych seryny i treoniny znajdujących się w tych białkach.


Abstract 69%

They are also sensitive to EGFR tyrosine kinase inhibitors (TKIs), which provide superior clinical benefits to conventional chemotherapy.


2013 Cumberworth BiochemJ 67%

[34] found transient hubs to be enriched in kinase functions, and that the partners of transient hubs had significantly higher levels of disorder than the average level of disorder of proteins in the network.


ER1225 62%

Jean Soulier (Paris) 14:20-14:35 14:35-14:40 TCR and T-ALL Discussion Elizabeth Macintyrc (Paris) 14:40-14:55 Jan Cools (Leuven) 14:55-15:00 Targeting oncogenic NOTCH 1 signaling in T-ccll acute lymphoblastic leukemia Discussion 15:00-15:15 15:15-15:20 IL7R AND PTEN Discussion Joao Barata (Lisbon) 15:20-15:35 15:35-15:40 JAK/STAT signaling in T-ALL Discussion Pieter Van Vlierbcrghe (Ghent) 15:40-15:55 Deletion 6q impairs ribosomal and mitochondrial functions Jean Soulier (Paris) to drive leukemia progression in T-ALL Discussion 15:55-16:00 16:07-16:10 The nucleotide kinase Nadk constitutes a metabolic vulnerability o f NOTCH1-driven T-ALL Discussion 16:10-16:30 Panel discussion 16:30-17:00 Coffee Break 16:00-16:07 Etienne De Braekeleer (Cambridge) 2 SESSION III - INDIVIDUAL MANAGEMENT OF ALL Chair:


Nasarre Paper 60%

The motility and invasion of BLBC cells can require EGFR and ERK1/2 kinase activity (9);


ER1120 60%

focus on signaling kinase Stephan Stilgenbauer (Ulm) and apoptosis modulation Discussion 10:10-10:15 10:15-10:40 Gianluca Gaidano (Novara) 10:40-10:45 Mutations in CLL and how they affect therapy choice (focus on NOTCH 1, SF3B1, and TP53) Discussion 10:45-11:10 11:10-11:15 Genomic stratification for the treatment of lymphomas Discussion Laura Pasqualucci (New York) 11:15-11:40 11:40-11:45 Hairy cell leukaemia:


ER1031 53%

Nastoupil (Houston) 17:00-17:15 17:15-17:20 Management of comorbidity and specific adverse events in the era of novel kinase inhibitors (ibrutinib, idelalisib, venetoclax) for lymphoid malignancies Discussion 17:35-17:40 Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma Discussion 17:40-18:10 Round Table discussion 17:20-17:35 Farrukh Awan (Columbus) Loretta J.


constantes bio 52%

241 5 – 130 U/L 5 – 130 U/L Antigène prostatique spécifique (APS) Hommes ≥ 40 ans Bilirubine (CMC 2012) Totale Bilirubine conjuguée (directe) Calcium sérique (CMC 2012) Total Calcium ionisé Chlorures (CMC 2012) Cholestérolémie, LDL (CCS 2012) Patients à risque élevé (indice de risque de Framingham) Patient à risque intermédiaire si LDL ≥ 3,5 Patient à faible risque si LDL ≥ 5,0 Cholestérolémie, HDL Faible Cholestérolémie, totale Créatine kinase (CK ou CPK) (CMC 2012) Constantes biologiques – Page 2 Conseil de formation pharmaceutique continue Tableau 2 :


top-selling-kits-2016 52%

Kinase Urinary system Stem cell Neuroscience Apoptosis Cancer Innate immunity Endocrinology Development Immunomodulator Infectious Diseases Hematology Cardiovascular disease Globulins Autoimmunity Hypersensitivity 2 Focus on Lab Research, Service for Life Science.


2017 Colinet et al-Scientific Reports 52% OPEN Received:


[Thuc-tap]Hoa-sinh-II-HUMP 51%

Đo hoạt độ của CK (Creatine kinase) và CK-MB ........................................................................................................25 3.1.


Kasi - Vittal Poster - Final 49%

Vemurafenib is a potent inhibitor of the kinase domain in mutant BRAF, which prolongs progression-free and overall survival in melanoma patients with BRAF mutation but its use in BRAF mutated colon cancer is not well established.


DDND-2012-Program-low-res 47%



JDIT-2014-0921-003 45%

Some tumour cells are characterized by an increased uptake of choline and an over-expression of the genes encoding the choline kinase enzyme.